Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 9;13(8):1798.
doi: 10.3390/cancers13081798.

Tumor Microenvironment in Adrenocortical Carcinoma: Barrier to Immunotherapy Success?

Natalia Georgantzoglou  1 , Stefania Kokkali  1   2 , Gerasimos Tsourouflis  3 , Stamatios Theocharis  1
Affiliations
Review

Tumor Microenvironment in Adrenocortical Carcinoma: Barrier to Immunotherapy Success?

Natalia Georgantzoglou et al. Cancers (Basel). .

Abstract

Adrenocortical carcinoma is a rare malignancy with aggressive behavior, with up to 40% of patients presenting with metastases at the time of diagnosis. Both conventional chemotherapeutic regimens and novel immunotherapeutic agents, many of which are currently being tested in ongoing clinical trials, have yielded modest results so far, bringing the need for a deeper understanding of adrenal cancer behavior to the forefront. In the recent years, the tumor microenvironment has emerged as a major determinant of cancer response to immunotherapy and an increasing number of studies on other solid tumors have focused on manipulating the microenvironment in the favor of the host and discovering new potential target molecules. In the present review we aim to explore the characteristics of adrenocortical cancer's microenvironment, highlighting the mechanisms of immune evasion responsible for the modest immunotherapeutic results, and identify novel potential strategies.

Keywords: PDL-1; adrenocortical carcinoma; immune checkpoint inhibitors; immunotherapy; survival; tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Immune microenvironment in adrenocortical carcinoma.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. WHO . In: Classification of Tumors of Endocrine Organs WHO/IARC Classification of Tumors. 4th ed. Lloyd R.V., Osamura R.Y., Kloppel G., Rosai J., editors. Volume 10 WHO; Geneva, Switzerland: 2017.
    1. Berruti A., Grisanti S., Pulzer A., Claps M., Daffara F., Loli P., Mannelli M., Boscaro M., Arvat E., Tiberio G., et al. Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients with Radically Resected Adrenocortical Carcinoma. J. Clin. Endocrinol. Metab. 2017;102:1358–1365. doi: 10.1210/jc.2016-2894. - DOI - PubMed
    1. Berruti A., Terzolo M., Sperone P., Pia A., Della Casa S., Gross D.J., Carnaghi C., Casali P., Porpiglia F., Mantero F., et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: A large prospective phase II trial. Endocr. Relat. Cancer. 2005;12:657–666. doi: 10.1677/erc.1.01025. - DOI - PubMed
    1. Fassnacht M., Terzolo M., Allolio B., Baudin E., Haak H., Berruti A., Welin S., Schade-Brittinger C., Lacroix A., Jarzab B., et al. Combination Chemotherapy in Advanced Adrenocortical Carcinoma. N. Engl. J. Med. 2012;366:2189–2197. doi: 10.1056/NEJMoa1200966. - DOI - PubMed
    1. Megerle F., Herrmann W., Schloetelburg W., Ronchi C.L., Pulzer A., Quinkler M., Beuschlein F., Hahner S., Kroiss M., Fassnacht M., et al. Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma. J. Clin. Endocrinol. Metab. 2018;103:1686–1695. doi: 10.1210/jc.2017-02591. - DOI - PubMed

LinkOut - more resources